This is a routine annual meeting proxy solicitation with no contested items. The merger with Scancell Holdings plc will be addressed separately — monitor for the special meeting proxy statement and related filings for deal terms and shareholder vote details.
Price Chart
Executive Summary
Neuphoria Therapeutics Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on September 18, 2026, in connection with its upcoming Annual Meeting of Stockholders scheduled for November 2, 2026. The filing is a routine solicitation by management and does not involve any contested matters or activist demands — it relates solely to the annual meeting agenda (election of one Class II director, ratification of auditors, and approval of adjournments). The proxy statement explicitly states that the proposed merger with Scancell Holdings plc is not being voted on at this meeting and will be addressed at a separate special meeting.
Key Financial Metrics
Key Facts
- Annual Meeting scheduled for November 2, 2026, in virtual-only format
- Agenda includes: election of one Class II director, ratification of Wolf & Company P.C. as auditor, and approval of adjournments
- Proxy solicitation cost estimated at $20,000, with Sodali & Co. retained to assist
- Record date for voting is September 10, 2026
- The proposed merger with Scancell Holdings plc is explicitly excluded from this meeting and will be voted on at a separate special meeting
- Filing is by management (registrant), not a dissident or activist
Financial Impact
No financial impact from this filing — it is a routine proxy solicitation for the annual meeting. The estimated solicitation cost of $20,000 is immaterial.
Risk Factors
- Low risk — routine annual meeting with no contested proposals
- The separate merger vote (Scancell) introduces deal execution risk, but is not part of this filing
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-037146 |
| Document: 0001140361-26-037146-index-headers.html | 0001140361-26-037146 |
| Document: 0001140361-26-037146-index.html | 0001140361-26-037146 |
| Document: 0001140361-26-037146.txt | 0001140361-26-037146 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $3.44 | awaiting T+60 | — | $3.38 (−1.74%) |
Oct 5, 2026 21d ago | SC 13G | $3.45 | awaiting T+60 | — | $3.38 (−2.03%) |
Sep 18, 2026 5w ago | DEFA14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Sep 18, 2026 5w ago | DEFA14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Sep 18, 2026 5w ago | DEF 14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Jun 26, 2026 17w ago | Press Release | $4.40 $3.74 | ▼ −15.11% | ▼ −19.50% | $3.38 (−23.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers